Login
$ABOS
$0.20 -$0.01 (4.25%) Live

$ABOS SEC Filings

Filed On Filing
05 Nov 2026 8-K: Termination of a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities

As previously disclosed in its Current Report on Form 8-K filed on November 10, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement, dated November 10, 2023 (the “Loan Agreement”), with K2 Health...

30 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

28 Oct 2026 EFFECT
26 Oct 2026 S-3
26 Oct 2026 10-Q
26 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ...

16 Sep 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projec...

12 Aug 2026 DRS
12 Aug 2026 S-8
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

NEWTON, Mass., Aug. 12, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ...

17 Jun 2026 Form 4: Porter Derrell, Director

Received 6,460 shares by exercise or conversion ($6.91K) · Sold 6,460 shares ($15.1K) · Sold 12,800 shares ($29.8K) · 2 more

17 Jun 2026 144
16 Jun 2026 144
16 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

15 Jun 2026 144
10 Jun 2026 Form 4: Fountain Nathan B, Director

Sold 6,400 shares ($14.3K)

09 Jun 2026 144
05 Jun 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (Right to Buy)

05 Jun 2026 Form 4: Fountain Nathan B, Director

Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support